Displaying results 1 - 10 of 10
Metabolism, Alcohol & Toxicity
Non-alcoholic fatty liver disease: A patient guideline • This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. Click here to download the short version and here to download the publication in PDF format. EASL NAFLD-NASH Patient Guideline Short Version Non-alcoholic fatty liver disease: A patient guideline
EASL Studio Podcast S3 E6: How to improve end-of-life care in liver disease? • Description In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines: When is the best time to think about end-of-life care in liver disease? What does it mean for the liver care team? When and how should patients be referred to specialised palliative care? Faculty Dr Patrizia Künzler-Heule (Moderator) Prof. Philip Larkin (Faculty) Dr Philip Berry (Faculty) Listen to the podcast
COVID-19 and the liver
Ask EASL: podcast on COVID-19 vaccination in patients with liver disease • Ask EASL is an ongoing series of educational podcasts dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations. They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.
Ask EASL: podcast on Liver Cancer • Ask EASL is a new series of educational content dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this audio interview conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.